sildenafil aristo 100mg potahovaná tableta
aristo pharma gmbh, berlin array - 15560 sildenafil-citrÁt - potahovaná tableta - 100mg - sildenafil
sildenafil aristo 25mg potahovaná tableta
aristo pharma gmbh, berlin array - 15560 sildenafil-citrÁt - potahovaná tableta - 25mg - sildenafil
sildenafil aristo 50mg potahovaná tableta
aristo pharma gmbh, berlin array - 15560 sildenafil-citrÁt - potahovaná tableta - 50mg - sildenafil
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - hydrochlorid klopidogrelu - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotické činidla - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
hedonin prolong 200mg tableta s prodlouženým uvolňováním
g.l. pharma gmbh, lannach rakousko - 14951 kvetiapin-fumarÁt - tableta s prodlouženým uvolňováním - 200mg - kvetiapin
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - astma - léky na obstrukční onemocnění dýchacích cest, - budesonid / formoterol teva pharma b. je indikována pouze u dospělých ve věku 18 let a starších. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
maratia 37,5mg/325mg tableta
g.l. pharma gmbh, lannach array - 2719 tramadol-hydrochlorid; 1064 paracetamol - tableta - 37,5mg/325mg - tramadol a paracetamol
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimethyl fumarát - roztroušená skleróza, relaps-remitentní - imunosupresiva - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
ambrisentan aop 10mg potahovaná tableta
aop orphan pharmaceuticals gmbh, wien array - 16475 ambrisentan - potahovaná tableta - 10mg - ambrisentan
ambrisentan aop 5mg potahovaná tableta
aop orphan pharmaceuticals gmbh, wien array - 16475 ambrisentan - potahovaná tableta - 5mg - ambrisentan